Company intelligence / Profile preview

Immunoah Therapeutics, Inc.

Ownership: Private
Development stage: Other

Overview

Immunoah Therapeutics is developing novel agonist monoclonal antibodies for cancer immunotherapy. Lead candidates have demonstrated potent immunological enhancement and anticancer effects in preclinical studies. At least three programs have entered Phase 1 clinical trials targeting solid tumors and advanced malignancies.[3][6] The company has outlicensed rights to some assets in China.[6]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Bispecific T-cell engagers (BiTEs)Bispecific antibodiesTrispecific T-cell engagers (TriTEs)[3][6]
Industry: Biotech

Drug pipeline

12 assets

IMM092

11 more assets in the full pipeline.

Partnerships

Rights to lead product candidate Zymwolumab were licensed out in China to a pharmaceutical partner in 2017.[6]Actively seeking further collaborations at all levels.[1]

Beyond the preview

Go deeper on Immunoah Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoah Therapeutics, Inc..